WHO backs Regeneron COVID-19 drug cocktail – with equal access and price cut
“This is a major breakthrough in the care of COVID-19 patients”, said Dr. Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”. Effective ‘reduction in mortality’ WHO’s conditional recommendations are for use of the drug…
Read More
